Claims
- 1. A wound healant composition comprising a therapeutically effective amount of activated platelet concentrate and ascorbic acid.
- 2. A wound healant described in claim 1, wherein said ascorbic acid is present in an amount ranging between about 20 mg and about 65 mg per ml of activated platelet concentrate.
- 3. A wound healant described in claim 1, wherein said activated platelet concentrate results from the inclusion of an agonist to activate a platelet concentrate.
- 4. A wound healant described in claim 3, wherein said agonist is selected from the group consisting of thrombin, collagen, serotonin, adenosine diphosphate (ADP) and acetylcholine (ACH), and combinations thereof.
- 5. A wound healant described in claim 1, wherein said growth factors are included within concentrated platelets, and said activation results from the inclusion of thrombin.
- 6. A wound healant described in claim 5, wherein said concentrated platelets are autologous concentrated platelets and having a white blood cell count of below about 3 time 107 cells/ml.
- 7. A wound healant composition comprising a therapeutically effective amount of concentrated platelets, ascorbic acid and thrombin.
- 8. A wound healant composition comprising a therapeutically effective amount of concentrated platelets, at least one anti-oxidant and thrombin.
- 9. A wound healant composition described in claim 8, wherein said anti-oxidant comprises a retinoid, vitamin E, or β-carotene.
- 10. A wound healant composition described in claim 9, wherein said retinoid is vitamin A.
- 11. A wound healant composition comprising a therapeutically effective amount of concentrated platelets, at least one antibiotic and thrombin.
- 12. A wound healant described in claim 11, wherein said antibiotic is bacteriocidal to at least Pseudomonas and Klebsella bacteria.
- 13. A wound healant described in claim 11, wherein said antibiotic is selected from the group consisting of a neosporin, vancomycin and gentamycin, and combinations thereof.
- 14. A wound healant composition comprising concentrated platelets, ascorbic acid, at least one retinoid, at least one antibiotic bacteriocidal to at least Pseudomonas and Klebsella and thrombin.
- 15. A wound healant composition comprising concentrated platelets in an amount ranging between about 350,000 and about 2×106 cells/ml, ascorbic acid in an amount ranging between about 20 mg and about 65 mg/ml, thrombin in an amount ranging between about 100 U and about 10,000 U, preferably about 900 U and about 1100 U, most preferably about 1000 U per 8 cc of platelet concentrate, and calcium chloride in an amount ranging between about about 0.1 mg/ml and about 10 mg/ml.
- 16. A wound healant composition as described in claim 15, further comprising vitamin A and vitamin E in effective anti-oxidative amounts.
- 17. A method of making a wound healant composition, comprising the steps of mixing, in therapeutically effective amount(s), activated platelet concentrate with ascorbic acid.
- 18. A method of making a wound healant described in claim 17, wherein said activated platelet concentrate are obtained by the steps of sequestering concentrated platelets and mixing thrombin with said platelets.
- 19. A method of making a wound healant described in claim 17, said method further comprising, prior to mixing said thrombin, mixing at least one retinoid in sufficient amount(s) to further enhance wound healing.
- 20. A method of making a wound healant described in claim 22, wherein said retinoid is vitamin A in sufficient amount to reduce any non-responsiveness of the wounded's immune system to stimuli, and vitamin E in sufficient amount to further enhance wound healing.
- 21. A method of making a wound healant described in claim 23, wherein vitamin and vitamin E are admixed with concentrated platelets and ascorbic acid, then admixed with thrombin with calcium chloride.
- 22. A method of making a wound healant described in claim 17, said method further comprising, prior to mixing said thrombin, mixing at least one antibiotic in sufficient amount(s) to reduce infection by bacteria.
- 23. A method of making a wound healant described in claim 22, wherein said antibiotic is at least bacteriocidal to Pseudomonas and Klebsella bacteria.
- 24. A method of making a wound healant described in claim 22, wherein said antibiotic is selected from the group consisting of neosporin, vancomycin and gentamycin, and combinations thereof.
- 25. A method of making a wound healant, comprising the steps of, prior to mixing thrombin, admixing, in therapeutically effective amount(s), concentrated platelets, ascorbic acid, at least one retinoid and at least one antibiotic bacteriocidal to at least Pseudomonas and Klebsella bacteria.
- 26. A method of making a wound healant composition, comprising the steps of: extracting blood from a patient, centrifuging said blood until the appearance of an essentially separate band of plasma, an essentially separate band of red blood cells, and an essentially intermediate grouping comprised of concentrated platelets therebetween; removing said plasma band; centrifuging said remaining blood components at said speed an sufficient duration; removing said concentrated platelets; and mixing, in therapeutically effective amount(s), said concentrated platelets with thrombin and ascorbic acid.
- 27. A wound healant prepared in accordance with claims 17-24.
- 28. A wound healant prepared in accordance with claim 25.
- 29. A wound healant prepared in accordance with claim 26.
- 30. A method of treating a wound, comprising the steps of applying a sufficient amount of composition of matter comprising a therapeutically effective amount of activated platelet concentrate and ascorbic acid to enhance healing of the wound.
- 31. A method of treating a wound described in claim 30, wherein said activation results from the inclusion of an agonist.
- 32. The method of treating a wound described in claim 31, wherein said agonist is selected from the group consisting of thrombin, collagen, serotonin, ADP and acetylcholine (ACH), and combinations thereof.
- 33. A method of treating a wound described in claim 30, wherein said growth factors are derived from concentrated platelets, and said activation results from the inclusion of thrombin.
- 34. A method of treating a wound described in claim 30, wherein said concentrated platelets are autologous concentrated platelet.
- 35. A method of treating a wound described in claim 30, said wound healant composition comprising concentrated platelets, ascorbic acid and thrombin.
- 36. A method of treating a wound described in claim 30, said wound healant composition comprising concentrated platelets and thrombin, and further comprising at least one retinoid.
- 37. A method of treating a wound described in claim 36, wherein said retinoid is vitamin A.
- 38. A method of treating a wound described in claim 36, wherein said retinoid is vitamin E.
- 39. A method of treating a wound described in claim 30, said wound healant composition comprising concentrated platelets and thrombin, and further comprising at least one antibiotic.
- 40. A method of treating a wound described in claim 39, wherein said antibiotic is bacteriocidal to at least Pseudomonas and Klebsella bacteria.
- 41. A method of treating a wound described in claim 39, wherein said antibiotic is selected from the group consisting of a neosporin, vancomycin and gentamycin, and combinations thereof.
- 42. A method of treating a wound described in claim 30, said wound healant composition comprising concentrated platelets, ascorbic acid, at least one retinoid, at least one antibiotic bacteriocidal to Pseudomonas and Klebsella bacteria, and thrombin.
CROSS-REFERENCE
[0001] This application is a continuation-in-part of U.S. application Ser. No 09/424,523, filed Nov. 23, 1999, which is a continuation-in-part application of International application No. PCT/US99/02981, filed Feb. 13, 1999, which claims priority from U.S. provisional application Ser. No. 60/090,167 filed Jun. 22, 1998, and U.S. provisional application Ser. No. 60/097,897 filed Aug. 26, 1998.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60090167 |
Jun 1998 |
US |
|
60097897 |
Aug 1998 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09424523 |
Nov 1999 |
US |
Child |
09770924 |
Jan 2001 |
US |
Parent |
PCT/US99/02981 |
Feb 1999 |
US |
Child |
09424523 |
Nov 1999 |
US |